Sepracor Xopenex
Executive Summary
"Approvable" letter sent July 1 for Xopenex (levalbuterol) inhalation solution for the treatment of asthma. Sepracor submitted the NDA July 1, 1997. The company is building a 60-person sales force to market Xopenex